CIBC Bancorp USA’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
KCM
CIBC Bancorp USA's BEAM Position: Q3 2026 in Review
CIBC Bancorp USA increased its Beam Therapeutics (BEAM) stake by 57% in Q3 2026, buying an estimated $121K and bringing the position to 11,947 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #1702.
CIBC Bancorp USA first reported a position in BEAM in Q3 2025 and has held it in 3 quarters since. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- CIBC Bancorp USA held 11,947 shares of Beam Therapeutics worth $292K as of Q3 2026.
- CIBC Bancorp USA bought 4,329 Beam Therapeutics shares in Q3 2026, an estimated $121K.
- Beam Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1702 holding.
- CIBC Bancorp USA first reported a position in Beam Therapeutics in Q3 2025 and has held it in 3 quarters since.
- 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.